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Dear Colleagues, 
Humans need food (and love) to survive. At the evolu-
tionary level, the survival of biological species is me-
diated by growth, fertility and longevity phenotypes. 
However, the human race has evolved in an environ-
ment of extremely difficult periods of time, when food
was scarce. Hence, the act of hunting or gathering food 
was laborious and required higher energy expenditure 
than what it takes to have food nowadays. Such a sce-
nario promoted the ability to eat as much as was avail-
able. The “thrifty” genes may thus evolved to promote 
human survival in a life of famine-to-feast cycle (1). 
The scenario, especially in the economically advanced 
countries, has been changed in the last two decades: the 
average person has enough money to fill the daily ca-
loric needs with fast-food meals. And the average daily 
energy expenditure has declined in parallel with a sed-
entary lifestyle. Hence the evolutionary pattern of “the 
more you eat, the better for survival” became no longer 
an advantage but a liability, and the presence of Homo 
obesus is increasing dramatically (2 for adipochronobi-
ology of obesity and diabetes).
Today, Homo obesus (man the obese), like Diogenes 
(c. 403-323 BC), is increasingly saying “I am a citi-
zen of the world.” Recent studies provide evidence that 
morbid obesity is a major evil of human health, because 
plays a pivotal role in the development of cardiometa-
bolic diseases, such as atherosclerois, hypertension, 
type 2 diabetes mellitus, and metabolic syndrome as 
well as other disease such as nonalcocholic steato-
hepatitis, obstructive sleep apnea syndrome, polycystic 
ovary syndrome, and also Alzheimer’s disease. Each of 
V
Caesar:
Let me have men about me that are fat,
Sleek-headed men, and such as sleep a-nights:
Yond Cassius has a lean and hungry look;
He thinks too much: such men are dangerous.
William Shakespeare
Julius Caesar, Act 1, Scene 2
these diseases increases the risk of having an unsuc-
cessful ageing and a shortened life expectancy.
Both in financial terms and human suffering, the costs 
associated with obesity and related diseases are enor-
mous. An effective way to reduce the costs and increase 
the quality of life would be to treat one of the major un-
derlying causes, obesity. Currently available therapies 
employed to combat obesity have ranged from pharma-
ceuticals through modifications of lifestyle factors such
as nutrition and physical activity to caloric restriction 
mimetics (3-6), incretin-based drugs (7), vaccination 
(8), and omics-based personalized treatment (9,10) 
However, these treatments have disadvantages such as 
transient effectiveness and undesirable side effects of 
pharmaceuticals, poor compliance for lifestyle modifi-
cations, whereas the experience from recently applied 
biologicals and gene/cell therapy (11) is controversial.
In most countries the prevalence of obesity now ex-
ceeds 15%, the figure used by the World Health Organi-
zation (WHO) to define the critical threshold for inter-
vention in nutritional epidemics (12). The prevalence of 
adult obesity has exceeded 30% in the United States, is 
over 20% in most of Europe, and is 40-70% in the Gulf 
and Polynesian islands. Further, WHO’s data show that 
20 percent of European children are overweight and that 
their number increases by 400,000 a year. In a similar 
vein, “for the first time in American history, todays’s
generation of children could live shorter lives than their 
parents. The cuase is obesity: more than 11 million chil-
dren in the United States are with overweight or obese, 
thousands of them being with type 2 diabetes mellitus.” 
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This provoked a joint activity of Clinton Global Initia-
tive (an NGO of philantropic purposes) and the Ameri-
can Heart Asociation, and they launched in 2005 the Al-
liance for a Healthier Generation. This health promot-
ing activity may be a role model for other countries.
Dr Ludovicus Nonnius was born in Antwerp, Bel-
gium in 1553 (13). He built up an important practice as 
physician, naturalist, writer, and latin poet, thus being 
a good example of a Renaissance humanist. He died in 
1645 at the age of 92. A special merit of the author is 
that he can be considered to be the founder of medical 
dietetics; his friend, the famous artist Peter Paul Rubens 
(1577-1640), also appreciated his dietary prescriptions. 
The main work of Nonnius is his "Diaeteticon sive de re 
cibaria libri IV", where he exposes the basic principles 
of healthy eating. He asserts that eating vegetables, fruits 
and fish is very healthy. And also talks about the benefits
of drinking wine, eight chapters being dedicated to eno-
therapy wine (from Greek oinos - wine). The Antwerp 
scholar agrees with Hippocrates and also Galen, who 
teaches that "red wines produce much blood, so that are 
proper to feed the body.” Recently, oenology (enology) 
(14) and also xenohormesis (3) have made enormous 
progress based upon serious scientific research (4-6).
Likewise, various “-omics” sciences (9,10), adipobiol-
ogy and (adipo)pharmacology (7,15,16) are contribut-
ing to a better understanding of health and disease. And 
may hopefully enable us to phenotypically modulate 
Homo obesus into being like yond Cassius lean and 
thinks too much. Hence, dangerous for local and global 
stupidity and selfishness.
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